Photodynamic Therapy in Adolescents Halitosis

Halitosis Clinical Trial

Official title:

Photodynamic Therapy as Novel Treatment for Halitosis in Adolescents: Crontolled Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02007993
• Other study ID #: halitose01
• Status: Recruiting
• Phase: N/A
• First received: November 26, 2013
• Last updated: July 31, 2014
• Start date: November 2013
• Est. completion date: October 2014

Study information

• Verified date: December 2013
• Source: University of Nove de Julho
• Contact: Rubia G Lopes, master
• Phone: 55 11 985939878
• Email: rubia.lopes.rl[@]gmail.com
• Is FDA regulated: No
• Health authority: Brazil: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The aim of the proposed controlled clinical trial is to evaluate the effect of photodynamic therapy (PDT) on the formation of volatile sulfur compounds (VSCs) from coated tongue and its action on the severity of halitosis in adolescents using different treatment protocols.

HYPOTHESIS

1. - Null hypothesis: There is no change in halitosis following the use of photodynamic therapy.

2. - Experimental hypothesis: There is a reduction in halitosis following the use of photodynamic therapy alone or in combination with a tongue scraper.

Description:

Halitosis (bad breath) is a term used to describe an unpleasant odor emanating from the mouth that could originate in the oral cavity itself or as a result of systemic factors. Halitosis is a common problem that affects most of the population worldwide and is caused mainly by the volatile sulfur compounds produced by anaerobic Gram-negative microorganisms in the oral cavity on sulfur-containing substrates in the oral cavity. On the dorsum of the tongue, the volatile sulfur compounds produced from this metabolism are hydrogen sulfide (H2S), methyl mercaptan (CH3SH3) and dimethyl sulfide (CH3-S-CH3). The concentration of these gases is used as an indicator of the severity of halitosis. Recently, the Gram positive anaerobic bacterium Solobacterium moorei (formerly known as Bulleidia moorei) has also been associated with oral malodor by volatile sulfur compounds production, particularly hydrogen sulfide in the presence of different supplements with amino acids more specifically cysteine, wich agrees with studies showing that the cysteine challenge is a in vivo and in vitro model for analyzing the production of hydrogen sulfide.

The measure of volatile sulfur compounds can be performed by an organoleptic evaluation of the air emanating from the oral cavity through gas chromatography or the use of a sulfide monitor, such at the Halimeter (Interscan Corporation), which determines the amount of volatile sulfur compounds in parts per billion (ppb) in the exhaled air. Gas chromatography is the most appropriate means for detecting halitosis of different origins. In 2004, the Oral ChromaTM (Abilit Corporation) was developed in Japan for the individual measurement of the three main gases (hydrogen sulfide, methyl mercaptan and dimethyl sulfide), allowing the evaluation of the intensity and origin of halitosis.

Light, either alone or in combination with chemical compounds, has been used for its therapeutic and antimicrobial effects. Photodynamic therapy encompasses the simultaneous action of a light source and photosensitizing agent in the presence of oxygen in tissues. Individually, each of these substances is innocuous, but their interaction is capable of giving rise to cytotoxic species that lead to cell death.The advantage of this approach is the avoidance of the development of resistance on the part of the target bacteria and damage to the adjacent tissues, since the antimicrobial effect is confined to the area covered by the dye and irradiated by the light, acting quickly on the target organisms. The efficacy of photodynamic therapy depends on the energy dose and output power employed.

Evaluation of degree of halitosis:

The portable Oral ChromaTM device (Abilit, Japan) will be employed. This device uses a highly sensitive gas semiconductor sensor.It will be connected to the computer with a specific software program that allows the creation of a graph corresponding to the peaks and concentrations of gases, measuring the VSC thresholds (0 to 1000 ppb), with considerable precision after eight minutes.

Analysis of volatile sulfur compounds:

• Hydrogen sulfide: values greater than 112 ppb indicate halitosis (SH2 ≥ 112 ppb);

• Methyl mercaptan: values greater than 26 ppb indicate halitosis (CH3SH ≥ 26 ppb);

A quantitative, controlled, cross-sectional, clinical trial will be carried out involving 130 teenagers. All individuals will be submitted to evaluations with Oral ChromaTM for the diagnosis of halitosis (scores SH2 ≥ 112 ppb and CH3SH ≥ 26 ppb) at the beginning of the study. Three post-treatment evaluations will be carried out: one hour, 24 hours and one week after treatment. The subjects selected will be randomly allocated to five groups:

1. Group 1 will receive treatment with a tongue scraper;

2. Group 2 and 3will receive photodynamic therapy applied to the posterior two thirds of the dorsum of the tongue;

3. Groups 4 and 5 will receive combined treatment (tongue scraper and photodynamic therapy).

The statistical analysis will include the chi-square test and Fisher's Exact Test. The Student's t-test and analysis of variance (ANOVA) will be used for the comparison of means. Pearson's correlation coefficients will be calculated to determine the strength of correlations between continuous variables. A 95% significance level will be considered on all statistical tests (p < 0.05).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 130
• Est. completion date: October 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 14 Years to 21 Years

Eligibility

Inclusion Criteria:

• Signed statement of informed consent;

• Authorization by legal guardian for the diagnosis and treatment of halitosis (Appendix 2);

• Halitosis score using cysteine: S2H = 112 ppb and/or CH3SH = 26 ppb (Oral ChromaTM).

Exclusion Criteria:

• Dental-facial anomalies;

• Currently undergoing orthodontic and/or orthopedic treatment;

• Use of removable appliance, implant or denture;

• Periodontal disease;

• Teeth with carious lesions;

• Currently undergoing cancer treatment;

• History of antibiotic treatment in previous month;

• Pregnancy;

• Hypersensitivity to the photosensitizing agent employed.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Halitosis

Intervention

Other:
• PDT
A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue. Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5
• Tongue Scraper
The pacient will scrap the tongue 10 times.

Locations

Country	Name	City	State
Brazil	Universidade Nove de Julho	SP

Sponsors (1)

Lead Sponsor	Collaborator
University of Nove de Julho

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Halitosis Scores	It will be compare de score of voalitile sulfur compounds in parts per billion (ppb) of hydrogen sulfide (H2S) and methyl mercaptan (CH3SH3).	Prior to the initial photodynamic therapy on day 1 and 1, 24 and 168 hours post-photodynamic therapy	No
Secondary	Microbiological Analysis	Microbiological analyses of coated tongue will be performed before and after treatment using a 1-µl inoculation loop for the collection of biofilm samples from the dorsum of the tongue. The samples will be transferred to 1.5-ml vials with reduced transport fluid and placed in a vortex mixer for approximately 30 seconds for homogenization. Ten-fold serial dilution will be prepared in 180 µl of sterile phosphate buffered saline and aliquots of 10-2, 10-3, 10-4 and 10-5 will be transferred to plates with brain heart infusion agar. As the main bacteria responsible for the production of VSCs are Gram-negative, the plates will be incubated in anaerobic jar for 72 h at 37 °C, following by the quantification of colony-forming units (CFUs)	Prior to the initial photodynamic therapy on day 1 and 1 and 24 hours post-photodynamic therapy	No